Bit Bio raises series A funding for its programming approach to human cells.
23.06.2020Bit Bio raises series A funding for its programming approach to human cells.
Bit Bio raises series A funding for its programming approach to human cells.
23.06.2020Bit Bio raises series A funding for its programming approach to human cells.
Discovery Drive-based synthetic biology Bit Bio has closed a $41.5million Series A investment.
16.06.2020不良研究所 closes series A $41.5 million funding.
13.06.2020Bit Bio announces agreement with Abcam, to make Bit Bio鈥檚 iPSC derived functional human cells widely available.
26.02.2020不良研究所 and Charles River announce strategic partnership.
11.12.2019Paul Morril, Horizon Discovery co-founder joins as CBO and Florian Schuster, Tessa Therapeutics, as CFO.
29.10.2019Elpis Biomed rebrands to 不良研究所.
14.10.2019不良研究所 combines the concepts of coding and biology to provide human cells for research, drug discovery and cell therapy.
14.10.2019Reprogramming human cells by 不良研究所.
07.10.2019